Dogwood Therapeutics, Inc. (DWTX) Press Releases https://ir.dwtx.com/news/press-releases/rss Please specify a description for this RSS Feed en-us https://d1io3yog0oux5.cloudfront.net/_9f55823e9477de6aca19e5bcf0d048d4/virios/files/theme/images/DogwoodLogo.png Dogwood Therapeutics, Inc. Logo Equisolve Investor Relations Suite <![CDATA[Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results]]> https://ir.dwtx.com/news/press-releases/detail/151/dogwood-therapeutics-reports-fourth-quarter-and-full-year Wed, 18 Mar 26 08:30:00 -0400 https://ir.dwtx.com/news/press-releases/detail/151/dogwood-therapeutics-reports-fourth-quarter-and-full-year <![CDATA[Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026]]> https://ir.dwtx.com/news/press-releases/detail/150/dogwood-therapeutics-announces-50-enrollment-in-ongoing Mon, 02 Feb 26 08:30:00 -0500 https://ir.dwtx.com/news/press-releases/detail/150/dogwood-therapeutics-announces-50-enrollment-in-ongoing <![CDATA[Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development]]> https://ir.dwtx.com/news/press-releases/detail/149/dogwood-therapeutics-inc-announces-financing-of-up-to Mon, 12 Jan 26 08:30:00 -0500 https://ir.dwtx.com/news/press-releases/detail/149/dogwood-therapeutics-inc-announces-financing-of-up-to <![CDATA[Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain]]> https://ir.dwtx.com/news/press-releases/detail/148/dogwood-therapeutics-announces-positive-interim-phase-2b Mon, 22 Dec 25 10:15:00 -0500 https://ir.dwtx.com/news/press-releases/detail/148/dogwood-therapeutics-announces-positive-interim-phase-2b <![CDATA[Dogwood Therapeutics Files New Synthetic Halneuron(R) Intellectual Property Protection Projected to Extend Exclusivity Period Up to 2045]]> https://ir.dwtx.com/news/press-releases/detail/147/dogwood-therapeutics-files-new-synthetic-halneuronr Tue, 02 Dec 25 08:00:00 -0500 https://ir.dwtx.com/news/press-releases/detail/147/dogwood-therapeutics-files-new-synthetic-halneuronr <![CDATA[Dogwood Announces Enrollment of First 100 Patients in Ongoing Halneuron(R) Phase 2b Trial, Interim Sample Size Analysis on Track for December 2025]]> https://ir.dwtx.com/news/press-releases/detail/146/dogwood-announces-enrollment-of-first-100-patients-in Tue, 11 Nov 25 08:45:00 -0500 https://ir.dwtx.com/news/press-releases/detail/146/dogwood-announces-enrollment-of-first-100-patients-in <![CDATA[Dogwood Therapeutics Reports Third Quarter 2025 Financial Results]]> https://ir.dwtx.com/news/press-releases/detail/145/dogwood-therapeutics-reports-third-quarter-2025-financial Thu, 06 Nov 25 08:45:00 -0500 https://ir.dwtx.com/news/press-releases/detail/145/dogwood-therapeutics-reports-third-quarter-2025-financial <![CDATA[Dogwood Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025]]> https://ir.dwtx.com/news/press-releases/detail/144/dogwood-therapeutics-to-report-third-quarter-2025-financial Thu, 30 Oct 25 09:15:00 -0400 https://ir.dwtx.com/news/press-releases/detail/144/dogwood-therapeutics-to-report-third-quarter-2025-financial <![CDATA[Dogwood Therapeutics to Participate at the Maxim Growth Summit 2025]]> https://ir.dwtx.com/news/press-releases/detail/143/dogwood-therapeutics-to-participate-at-the-maxim-growth Tue, 14 Oct 25 08:45:00 -0400 https://ir.dwtx.com/news/press-releases/detail/143/dogwood-therapeutics-to-participate-at-the-maxim-growth <![CDATA[Dogwood Therapeutics, Inc. Chief Medical Officer, Dr. Michael Gendreau, to Present an Overview of the Halneuron® Pain Research Program at the 19th Annual Pain Therapeutics Summit]]> https://ir.dwtx.com/news/press-releases/detail/142/dogwood-therapeutics-inc-chief-medical-officer-dr Tue, 07 Oct 25 08:45:00 -0400 https://ir.dwtx.com/news/press-releases/detail/142/dogwood-therapeutics-inc-chief-medical-officer-dr